The proteasome inhibitor bortezomib has been shown to possess promising antitumor
activity and significant efficacy against a variety of malignancies. Different studies …

Bortezomib (BZ) is the first clinically approved proteasome inhibitor that has shown
remarkable anticancer activity in patients with hematological malignancies. However, many …

The ubiquitin-proteasome pathway is responsible for degrading many critical regulatory
proteins involved in immune and inflammatory responses, control of cell growth and …

: XIAP is a member of the inhibitors-of-apoptosis family of proteins, which inhibit caspases
and block cell death, with prognostic importance in AML. Here we demonstrate that …

Proteasome-regulated NF-κB has been shown to be important for cell survival in T-cell
lymphoma and Hodgkin lymphoma models. Several new small-molecule proteasome …

Resistance to currently available therapies is a major impediment to the successful
treatment of hematological malignancies. Here, we used a model of therapy-resistant B-cell …

Bortezomib (Velcade®) exploits proteasome inhibition as a unique mechanism of anticancer
activity. The effectiveness of bortezomib is, however, limited, therefore, the search for …

Bortezomib is a proteasome inhibitor with proven efficacy in multiple myeloma and non–
Hodgkin's lymphoma. This study reports the effects of bortezomib in B-cell lymphoma cell …

Bortezomib (BTZ), a proteasome inhibitor, is the first proteasome inhibitor to be used in
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …

Bortezomib, a proteasome inhibitor that was originally developed as an inhibitor of nuclear
factor‐κB pathways, is currently used for the treatment of multiple myeloma (MM) and mantle …